Nuclear interaction of Arp2/3 complex and BRAF^V600E promotes aggressive behavior and vemurafenib resistance of thyroid cancer.

ABSTRACT: The presence of mutant BRAF ^V600E correlates with the risk of recurrence in papillary thyroid cancer (PTC) patients. However, not all PTC patients with BRAF ^V600E are associated with poor prognosis. Thus, understanding the mechanisms by which certain PTC patients with nuclear BRAF ^V600E become aggressive and develop resistance to a selective BRAF inhibitor, PLX-4032, is urgently needed. The effect of nuclear localization of BRAF^V600E using in vitro studies, xenograft mouse-model and human tissues was evaluated. PTC cells harboring a nuclear localization signal (NLS) of BRAF^V600E were established and examined in nude mice implanted with TPC1-NLS-BRAF^V600E cells followed by PLX-4032 treatment. Immun

SUBMITTER: Zerfaoui M 

PROVIDER: S-EPMC9360225 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature